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ABSTRACT
PURPOSE: The objectives were to determine the effects of oral contraceptives and the
menstrual cycle on the benefits of caffeine supplementation for cycling performance.
METHODS: Seventeen recreationally trained female cyclists, oral contraceptive users
(n=9) and non-users (n=8), completed four trials consisting of 3-km time trials (TT).
Subjects ingested either 6mg/kg of caffeine or a placebo one hour prior to each trial.
Magnitude based inferences were used to evaluate treatment differences. RESULTS:
***TBD. CONCLUSIONS:*** TBD.

INTRODUCTION
Caffeine is often consumed for its stimulating effects and ability to improve
physical performance (5). There is good evidence that caffeine supplementation can
enhance physical performance ranging from peak strength to endurance performance (3–
5, 10, 15, 20, 22, 49, 51, 55, 56). The optimal caffeine dose for performance benefits is
between 3 and 6 mg of caffeine per kilogram of body mass (13, 20, 22, 51).
The pharmokinetics of caffeine is predominantly regulated by hepatic cytochrome
P450 (CYP1A2), the enzyme responsible for metabolizing the majority of caffeine (17,
37, 40, 41, 52, 59). Therefore, different concentration/activity levels of CYP1A2
represents a major source of variability in the pharmacokinetics of caffeine (58).
Demethylation is the first step to caffeine metabolism, and is mostly metabolized to form
paraxanthine (29). Less is known about paraxanthine kinetics and its potential role in
facilitating beneficial effects of caffeine on exercise performance (10), however, caffeine
metabolites have an even higher affinity for the adenosine receptors, which stimulate the
central nervous system (11, 18), thereby plausibly having an even greater effect on
performance than caffeine itself.
The rate of caffeine metabolism is not only sensitive to genetic variations of the
enzyme, but also biological sex (5, 29); specifically, female sex hormones, estrogen and
estradiol (1, 2, 17, 23, 42). There is an evident trend for higher plasma caffeine and lower
plasma paraxanthine concentrations in women compared to men, suggesting that women
metabolize caffeine slower than men (6). Women with higher estrogen levels, [such as
oral contraceptive steroid (OCS) users, females in the luteal phase, or pregnant], have
been found to have decreased CYP1A2 activity and decreased caffeine clearance (2, 32,

42). Despite the varying clearance rates across the menstrual cycle, currently nothing is
known about whether or not this impacts the performance response to caffeine intake.
Therefore, one of the primary aims of this study was to test the hypothesis that there will
be a magnified effect of caffeine on performance in the follicular phase compared to the
luteal phase.
The use of hormonal contraceptives is another condition when estrogen levels are
elevated, (50), possibly effecting the ergogenic effect of caffeine through dampening the
rate of caffeine metabolism. Chronic OCS use has been previously associated with
impaired metabolism of caffeine (1, 2, 40, 43, 47, 53). It is commonly reported that
OCS’s inhibit CYP1A2 activity (1, 2, 25, 43, 44, 53). OCS’s appear to modify the
metabolism of caffeine by reducing the formation of paraxanthine, which is the primary
pathway of caffeine metabolism, possibly limiting its physiological effects (44). There is
no current evidence of the interactive effect OCS use has on the ergogenic effect of
caffeine. Therefore, the second aim of this project is to test the influence of OCS use on
the performance response to caffeine supplementation compared to non-OCS users.
METHODOLOGY
Subjects
Twenty-eight healthy, recreationally trained female cyclists (15 OCS users, 13
non-users) from James Madison University and the greater Harrisonburg/ Rockingham
County area volunteered for the study. However, seven OCS users and four non-users
withdrew from the study due to injuries, Lyme disease diagnosis, switching birth control
prescription, seasonal flu, vasovagal syncope, or scheduling difficulties. Inclusion criteria
included: female, 18-35 years of age, non-smokers, cycle ≥ 30 minutes at least two days a

week, and VO2max ≥ 40 ml/kg/min. Further, subjects were required to be eumenhorreic
with menstrual cycle length between 21-35 days over the past 6 months. Descriptive data
are shown in Table 1.0. Subjects who are not on any form of contraception will be
assigned to the control group (n=15), and the subjects on monophasic or tri-phasic oral
contraceptives will be assigned to the OCS user group (n=15). In the OCS user group,
subjects were limited to monophasic oral contraceptives or tri-phasic oral contraceptives
containing ethinyl estradiol and levonorgesterel for at least 6 months (8). Subjects were
fully informed about the experimental procedures and possible risks before given written
informed consent. Informed consent included information of the experimental procedures
and risks prior to participation. James Madison University Institutional Review Board
approved this study.
Experimental Design
Subjects reported to the laboratory for two familiarization trials and four
experimental trials. Two experimental trials (1 placebo and 1 caffeine) were conducted
during the luteal phase and two experimental trials (1 placebo and 1 caffeine) were
performed in the follicular phase of the menstrual cycle. The luteal phase trials were
performed from days 7 to 13 of the menstrual cycle, and the follicular phase trials were
performed from days 18 to 24. Each treatment trial was performed in the morning
between 6:00am and 10:00am. Trials were separated by at least 48 hours.
Preliminary Testing
Following height and body mass measurements, VO2max was assessed during an
incremental test on a bicycle ergometer (Velotron™ cycle ergometer, Racermate, Inc.
Seattle, WA, USA). Workload started at 50 W and was increased in 25 W increments

every minute until volitional fatigue, or pedaling rate dropped below 50 rpm for >10
seconds. Breath samples were collected and oxygen consumption was analyzed with a
Moxus® Modular Metabolic System (AEI Technologies, Pittsburgh, PA, USA). VO2max
was determined as the highest 30 second mean oxygen uptake value.
Supplementation
In a crossover, double-blind design, subjects were provided caffeine treatment or
placebo. Anhydrous caffeine at 6mg/kg body weight was measured into opaque gelatin
capsules. For placebo pills, gluten-free rice flour was put into opaque gelatin capsules.
Supplementation was ingested with water, 60 minutes prior to the performance trial.
Familiarization Trials
Two familiarization trials were completed on a Velotron™ cycle ergometer
before each subject began experimental trials. A 5-min self-selected warm-up was
performed before all 3-km time-trials. Subjects were instructed to approach the time trial
as a competition, emphasizing the importance to perform each trial as a race and put forth
100% effort. All trials were completed without verbal feedback and only elapsed distance
was displayed. The familiarization trial protocol was identical to the performance trials
with the exception of caffeine/placebo supplementation.
Performance Trials
Two venous blood samples were obtained; one upon arrival to the laboratory for
baseline caffeine measures and another 60 minutes post treatment, just prior to the
exercise trial. Following the second blood draw, subjects warmed-up on a treadmill for 5
minutes at 3.5 mph, followed by the 3k-time trial on a Velotron cycle ergometer. Subjects
were aware of the distance traveled and distance remaining during the trial, but were

blinded to time and wattage output. Performance was recorded in time to complete and
average watts for the 3-km time trial.
Blood Analysis
Approximately 3 ml of whole blood was obtained from an antecubital vein for
measures of caffeine and estrogen concentrations. Samples sat for 30 minutes to
coagulate, and then spun in a refrigerated centrifuge (AccuSpin™) at 2500 rpm for 15
minutes. Samples were subsequently decanted and plasma samples were stored in an 80oC freezer for analysis of serum caffeine levels.
Dietary and Exercise Control
Subjects completed 24-hour food logs and were instructed to replicate their diet
for 24 hours prior to each subsequent trial. Subjects were asked to refrain from any food
or drink (besides water) for four hours before and from caffeine and alcohol for 12 hours
before each trial. The OCS user group was required to authenticate intake of their
respective oral contraceptive within the past 24 hours. In addition, 48-hour physical
activity logs were completed prior to each trial, and were instructed to maintain
consistent exercise habits between trials. Subjects were asked to refrain from any
vigorous physical activity 12 hours prior to each trial.

